Mental disorders represent a considerable disease burden, and have a significant impact on the lives of the OECD population, and account for considerable direct and indirect costs. This report argues that even in those OECD countries with a long history of deinstitutionalisation, there is still a long way to go to make community-based mental health care that achieves good outcomes for people with severe mental illness a reality.
This new OECD series aims to highlight the latest data in selected countries, to explain their health care systems and to provide key information in a clear and concise way. Each country snapshot highlights the most pertinent issues, be it smoking, obesity, surgical interventions, consumption of antibiotics, physicians density, etc., with the help of key statistics and are followed by brief policy recommendations.
The OECD is launching an online consultation: tell us how we can improve sustainable access to innovative therapies!
Read about our groundbreaking event, the Health Forum and Ministerial, which took place on 16-17 January 2017. Health Ministers from OECD countries met in Paris to discuss The Next Generation of Health Reforms. You can also find here all about our latest reports: New Health Technologies: Managing Access, Value and Sustainability; Tackling Wasteful Spending on Health; and Caring for Quality in Health. And discover our latest videos.
The OECD Health Division is releasing a new series to highlight its work on health policies and data. A new graph will be available each month.
This High-Level Forum will be held at the OECD Conference Centre in Paris on 16 January 2017. Issues include: Harnessing digital technology and data to create proactive, people-centred systems; Overcoming technical, institutional and cultural challenges; Caring for people with complex needs; The importance of measuring what matters to people and to patients, and The role of international and cross-sector collaboration.
La multiplication de médicaments très onéreux et la hausse des prix des médicaments sont à l’origine de pressions de plus en plus lourdes sur les dépenses publiques de santé, et conduisent à remettre en question les stratégies tarifaires de l’industrie pharmaceutique.
Following a brief pause after the economic crisis, health expenditure is rising again in most OECD countries. Yet, a considerable part of this health expenditure makes little or no contribution to improving people's health. In some cases, it even results in worse health outcomes. Countries could potentially spend significantly less on health care with no impact on health system performance, or on health outcomes. This report systematically reviews strategies put in place by countries to limit ineffective spending and waste. On the clinical front, preventable errors and low-value care are discussed. The operational waste discussion reviews strategies to obtain lower prices for medical goods and to better target the use of expensive inputs. Finally, the report reviews countries experiences in containing administrative costs and integrity violations in health.
Antimicrobial resistance is a growing health and economic threat requiring multipronged responses. The OECD provides a forum for discussion and provide countries with the evidence to implement effective and cost-effective policies to tackle AMR, promote effective use of antimicrobials and incentivise research and development in the antibiotic sector.
This publication helps policy makers to better understand annuity products and the guarantees they provide in order to optimise the role that these products can play in financing retirement. Product design is a crucial factor in the potential role of annuity products within the pension system, along with the cost and demand for these products, and the resulting risks that are borne by the annuity providers. Increasingly complex products, however, pose additional challenges concerning consumer protection. Consumers need to be aware of their options and have access to unbiased and comprehensible advice and information about these products.